GSK Phase 2 Otilimab fails to meet Primary end point.
https://clinicaltrials.gov/ct2/show/NCT043766...amp;rank=1
For purposes of comparison and calibration to Brilacidin’s PH2:
GSK study NCT04376684 was first posted to clinicaltrials.gov on May 6th, 2020.
Phase 2.
800 participants/130 study locations.
Primary Outcome: Proportion of participants alive and free of respiratory failure at Day 28.
GSK fails COVID-19 phase 2, subgroup finding fuels further work
https://www.fiercebiotech.com/biotech/gsk-fai...=145171539
https://clinicaltrials.gov/ct2/show/NCT043766...amp;rank=1
For purposes of comparison and calibration to Brilacidin’s PH2:
GSK study NCT04376684 was first posted to clinicaltrials.gov on May 6th, 2020.
Phase 2.
800 participants/130 study locations.
Primary Outcome: Proportion of participants alive and free of respiratory failure at Day 28.
GSK fails COVID-19 phase 2, subgroup finding fuels further work
https://www.fiercebiotech.com/biotech/gsk-fai...=145171539